• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵形拟杆菌胆汁盐水解酶对艰难梭菌生长的抑制作用。

Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile.

机构信息

Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, 08826, Republic of Korea.

KoBioLabs, Inc., Seoul, 08826, Republic of Korea.

出版信息

J Microbiol. 2017 Nov;55(11):892-899. doi: 10.1007/s12275-017-7340-4. Epub 2017 Oct 27.

DOI:10.1007/s12275-017-7340-4
PMID:29076071
Abstract

Clostridium difficile infection (CDI) is one of the most common nosocomial infections. Dysbiosis of the gut microbiota due to consumption of antibiotics is a major contributor to CDI. Recently, fecal microbiota transplantation (FMT) has been applied to treat CDI. However, FMT has important limitations including uncontrolled exposure to pathogens and standardization issues. Therefore, it is necessary to evaluate alternative treatment methods, such as bacteriotherapy, as well as the mechanism through which beneficial bacteria inhibit the growth of C. difficile. Here, we report bile acid-mediated inhibition of C. difficile by Bacteroides strains which can produce bile salt hydrolase (BSH). Bacteroides strains are not commonly used to treat CDI; however, as they comprise a large proportion of the intestinal microbiota, they can contribute to bile acid-mediated inhibition of C. difficile. The inhibitory effect on C. difficile growth increased with increasing bile acid concentration in the presence of Bacteroides ovatus SNUG 40239. Furthermore, this inhibitory effect on C. difficile growth was significantly attenuated when bile acid availability was reduced by cholestyramine, a bile acid sequestrant. The findings of this study are important due to the discovery of a new bacterial strain that in the presence of available bile acids inhibits growth of C. difficile. These results will facilitate development of novel bacteriotherapy strategies to control CDI.

摘要

艰难梭菌感染(CDI)是最常见的医院获得性感染之一。由于抗生素的消耗,肠道微生物群落的失调是导致 CDI 的主要原因。最近,粪便微生物群移植(FMT)已被应用于治疗 CDI。然而,FMT 存在重要的局限性,包括对病原体的不可控暴露和标准化问题。因此,有必要评估替代治疗方法,如细菌疗法,以及有益细菌抑制艰难梭菌生长的机制。在这里,我们报告了胆汁酸介导的脆弱拟杆菌菌株抑制艰难梭菌的作用,这些菌株可以产生胆盐水解酶(BSH)。脆弱拟杆菌菌株通常不用于治疗 CDI;然而,由于它们构成了肠道微生物群落的很大一部分,它们可以有助于胆汁酸介导的抑制艰难梭菌。在存在卵形拟杆菌 SNUG 40239 的情况下,随着胆汁酸浓度的增加,对艰难梭菌生长的抑制作用增加。此外,当用胆酸螯合剂考来烯胺减少胆酸可用性时,对艰难梭菌生长的抑制作用显著减弱。由于发现了一种新的细菌菌株,在有可用胆汁酸的情况下,该菌株可以抑制艰难梭菌的生长,因此这项研究的结果非常重要。这些结果将有助于开发新的细菌疗法策略来控制 CDI。

相似文献

1
Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile.卵形拟杆菌胆汁盐水解酶对艰难梭菌生长的抑制作用。
J Microbiol. 2017 Nov;55(11):892-899. doi: 10.1007/s12275-017-7340-4. Epub 2017 Oct 27.
2
Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection.微生物胆汁盐水解酶介导粪菌移植治疗复发性感染的疗效。
Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11.
3
Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome.粪便微生物群移植对2例复发性艰难梭菌感染患儿的疗效及其对生长和肠道微生物组的影响
J Pediatr Gastroenterol Nutr. 2014 Nov;59(5):565-70. doi: 10.1097/MPG.0000000000000495.
4
Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.粪便微生物群移植成功治疗艰难梭菌感染
J Physiol Pharmacol. 2016 Dec;67(6):859-866.
5
Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth.粪便微生物群移植后结肠胆汁酸组成的变化足以控制艰难梭菌的萌发和生长。
PLoS One. 2016 Jan 20;11(1):e0147210. doi: 10.1371/journal.pone.0147210. eCollection 2016.
6
Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.艰难梭菌感染粪便微生物群移植成功后微生物群组成、胆汁和脂肪酸代谢的变化
BMC Gastroenterol. 2018 Aug 28;18(1):131. doi: 10.1186/s12876-018-0860-5.
7
A strain of Bacteroides thetaiotaomicron attenuates colonization of Clostridioides difficile and affects intestinal microbiota and bile acids profile in a mouse model.一株脆弱拟杆菌减轻艰难梭菌定植并影响小鼠肠道微生物群和胆汁酸谱。
Biomed Pharmacother. 2021 May;137:111290. doi: 10.1016/j.biopha.2021.111290. Epub 2021 Jan 25.
8
Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.艰难梭菌感染和无症状艰难梭菌定植中肠道微生物群变化的见解。
Anaerobe. 2015 Aug;34:1-7. doi: 10.1016/j.anaerobe.2015.03.008. Epub 2015 Mar 26.
9
Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.复发性艰难梭菌感染与独特的胆汁酸和微生物群谱相关。
Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53. doi: 10.1111/apt.13616. Epub 2016 Apr 18.
10
Shengjiang Xiexin decoction mitigates murine Clostridium difficile infection through modulation of the gut microbiota and bile acid metabolism.升陷泻心汤通过调节肠道微生物群和胆汁酸代谢减轻小鼠艰难梭菌感染。
J Ethnopharmacol. 2024 Feb 10;320:117384. doi: 10.1016/j.jep.2023.117384. Epub 2023 Nov 2.

引用本文的文献

1
New insights into microbial bile salt hydrolases: from physiological roles to potential applications.微生物胆汁盐水解酶的新见解:从生理作用到潜在应用
Front Microbiol. 2025 Feb 12;16:1513541. doi: 10.3389/fmicb.2025.1513541. eCollection 2025.
2
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.用于预防艰难梭菌感染的活体生物治疗产品的合理设计
J Infect Dis. 2024 Sep 24. doi: 10.1093/infdis/jiae470.
3
Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease.

本文引用的文献

1
Clostridium difficile infection.艰难梭菌感染。
Nat Rev Dis Primers. 2016 Apr 7;2:16020. doi: 10.1038/nrdp.2016.20.
2
Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.复发性艰难梭菌感染与独特的胆汁酸和微生物群谱相关。
Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53. doi: 10.1111/apt.13616. Epub 2016 Apr 18.
3
Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.艰难梭菌感染:流行病学、诊断和传播途径的理解。
卵形拟杆菌缓解菌群失调诱导的移植物抗宿主病。
Cell Host Microbe. 2024 Sep 11;32(9):1621-1636.e6. doi: 10.1016/j.chom.2024.08.004. Epub 2024 Aug 29.
4
Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections.胆汁酸与肠道微生物群的相互作用:感染的调节机制与治疗潜力
Pathogens. 2024 Aug 20;13(8):702. doi: 10.3390/pathogens13080702.
5
Rational Design of Live Biotherapeutic Products for the Prevention of Infection.用于预防感染的活体生物治疗产品的合理设计。
bioRxiv. 2024 May 2:2024.04.30.591969. doi: 10.1101/2024.04.30.591969.
6
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.胆汁酸、肠道微生物群与肝细胞癌的治疗新视角。
Cancer Biol Med. 2023 Dec 23;21(2):144-62. doi: 10.20892/j.issn.2095-3941.2023.0394.
7
Circulating neutrophil anti-pathogen dysfunction in cirrhosis.肝硬化患者循环中性粒细胞抗病原体功能障碍
JHEP Rep. 2023 Aug 1;5(11):100871. doi: 10.1016/j.jhepr.2023.100871. eCollection 2023 Nov.
8
Biofilm Formation of , Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI.艰难梭菌感染治疗中生物膜形成、毒素产生及传统抗生素替代方案
Microorganisms. 2023 Aug 26;11(9):2161. doi: 10.3390/microorganisms11092161.
9
Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans.粪便微生物移植对人类肠道细菌胆汁酸代谢的影响。
Nutrients. 2022 Dec 7;14(24):5200. doi: 10.3390/nu14245200.
10
Distinct Changes in Microbiota-Mediated Intestinal Metabolites and Immune Responses Induced by Different Antibiotics.不同抗生素诱导的微生物群介导的肠道代谢物和免疫反应的显著变化。
Antibiotics (Basel). 2022 Dec 6;11(12):1762. doi: 10.3390/antibiotics11121762.
Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16. doi: 10.1038/nrgastro.2016.25. Epub 2016 Mar 9.
4
Genetic determinants of in vivo fitness and diet responsiveness in multiple human gut Bacteroides.多种人体肠道拟杆菌体内适应性和饮食反应性的遗传决定因素。
Science. 2015 Oct 2;350(6256):aac5992. doi: 10.1126/science.aac5992.
5
Using a Novel Lysin To Help Control Clostridium difficile Infections.使用一种新型溶素来帮助控制艰难梭菌感染。
Antimicrob Agents Chemother. 2015 Dec;59(12):7447-57. doi: 10.1128/AAC.01357-15. Epub 2015 Sep 21.
6
Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?系统评价:胆汁酸与肠道炎症——管腔侵袭者还是黏膜防御调节因子?
Aliment Pharmacol Ther. 2015 Oct;42(7):802-17. doi: 10.1111/apt.13333. Epub 2015 Jul 29.
7
Clostridium difficile infection.艰难梭菌感染
N Engl J Med. 2015 Apr 16;372(16):1539-48. doi: 10.1056/NEJMra1403772.
8
Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model.解淀粉芽孢杆菌作为小鼠模型中艰难梭菌相关性疾病的预防性治疗手段
J Gastroenterol Hepatol. 2015 Aug;30(8):1275-80. doi: 10.1111/jgh.12957.
9
Metabolism of cholesterol and bile acids by the gut microbiota.肠道微生物对胆固醇和胆汁酸的代谢。
Pathogens. 2013 Dec 30;3(1):14-24. doi: 10.3390/pathogens3010014.
10
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.精准微生物群重建可恢复胆汁酸介导的对艰难梭菌的抗性。
Nature. 2015 Jan 8;517(7533):205-8. doi: 10.1038/nature13828. Epub 2014 Oct 22.